Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will present at the upcoming 2 nd Annual TGF-β for Immuno-Oncology Drug Development Summit ( tgf-beta-summit.com ), which will take place virtually from January 25, 2022 to January 27, 2022. “There is significant worldwide interest in the clinical application of anti-TGF-β inhibitors, in combination with checkpoint inhibitors, as well as other immuno-oncology and chemotherapeutic options. We look forward to sharing the clinical promise of OT-101 in this setting.” noted Dr. Anthony Maida, Chief Clinical Office – Translational Medicine. TGF-β has been recognized by drug developers, for many years, as holding vast therapeutic potential due to its vital role in cell functioning and signaling. But its complex nature and its ability to be both tumor promoting and tumor suppressing has presented many obstacles for the industry. However, the field appears to be at a tipping point at present, with more candidates moving through clinical evaluation, pointing to an explosion of new data on the way. “I am excited that we have the opportunity to join other professionals in the field in January to explore novel insights into targeting TGF-β from discovery through clinical testing, and to learn from fellow colleagues such as Genentech, AbbVie, Takeda, and Mestag Therapeutics.” noted Dr. Vuong Trieu, CEO and Chairman of Oncotelic. OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β through therapeutic use of OT-101 carries significant potential to help both cancer and COVID patients in the future. Recent analyst report for Oncotelic can be accessed here: http://www.hillsresearch.com/wp-content/uploads/2021/12/OTLC-3Q21.pdf Recent Dr. Anthony Maida interview on our clinical program can be accessed here: https://www.asbestos.com/news/2021/12/07/mesothelioma-trial-covid-19-drug/ About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019. For more information, please visit www.oncotelic.com Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-beta therapeutics for oncology and virology This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate", "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2021 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. Contact Details Amit Shah ashah@oncotelic.com Company Website https://www.oncotelic.com

December 14, 2021 09:01 AM Eastern Standard Time

Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease

Quidel Corporation

With Lyme disease being identified in record numbers throughout the country, Quidel releases a series of consumer-friendly infographics to help educate Americans on its characteristics, warning signs, seasonality and areas of prevalence. The infographics can be found at LymeDiseaseAnswers.com. “Lyme disease afflicts nearly 480,000 Americans each year; so people are rightfully concerned about where it is most pervasive, how to avoid getting it, and what to do if you think you may have been bitten by an infected tick,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel Corporation. “These infographics provide the information people are seeking in an easy-to-understand manner, and we encourage anyone who spends any time outdoors to educate themselves on this vitally important topic.” One infographic, for example, displays the early warning signs of Lyme disease—which could include headache, fatigue, a bulls-eye rash and muscle aches—while a second infographic depicts such late-stage symptoms as nerve pain, shortness of breath, brain fog and heart palpitations. There is an infographic showing the relative sizes of the larva, nymph and adult ticks; while still another infographic illustrates the evolution of these ticks through spring, summer, fall and winter. There is also a map showing those states where various types of ticks are most prevalent. Lyme disease can strike anyone of any age, especially those who spend time in wooded or grassy areas or who play sports on grass fields in high-risk areas of the country. The challenge is that unlike a mosquito bite where people know immediately if they have been bitten, deer ticks that may carry Lyme disease are tiny—the size of a poppy seed—and symptoms may not appear for two to six weeks. That makes it critically important that anyone who spends time outdoors in heavily wooded areas—hikers, hunters, campers—or travels to such places be particularly vigilant and educated. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia® 2 Lyme FIA test. This revolutionary test provides the patient and physician with indicative results within 15 minutes, as opposed to days, which has historically been the norm (and during which time organisms can spread and become systemic). It can be performed in the privacy of a doctor’s office or local clinic; and it is the only test that can get results from a simple finger prick of blood. In addition to the infographics, LymeDiseaseAnswers.com contains answers to frequently asked questions, the latest statistics and clinical research taking place regarding the disease, and links to additional resources on the subject. Also housed on the site is a series of attention-grabbing educational videos called “Quick Takes” that help consumers and health care professionals alike enhance their knowledge of Lyme disease by providing the information and up-to-the-minute data needed to confront this disease quickly and clearly. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, SofiaÂ®, SolanaÂ®, LyraÂ®, TriageÂ® and QuickVueÂ®, Quidel's comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. # # # Contact Details Jim Yeager +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

December 14, 2021 06:00 AM Pacific Standard Time

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 million ($1.29M) from the Israel Innovation Authority (IIA). This brings the total amount of financing raised by Kadimastem in 2021 to NIS 51.6 million ($16 M). As Kadimastem intends to submit the IND for the Phase IIa clinical study before the end of 2022, the IIA funding will be used to scale up the production of a frozen, off-the-shelf product of AstroRx® in preparation for the trial. Using large reactors and special tools, hundreds of millions of high-quality astrocyte cells, the brain supporting cells that comprise AstroRx®, will be produced for the clinical trial, as well as for future commercialization purposes for the benefit of the hundreds of thousands of ALS patients worldwide. Kadimastem has already completed a Phase I/IIa clinical trial ( ClinicalTrials.gov Identifier: NCT03482050 ). This trial was the first of its kind in the world, whereby the supporting cells of the central nervous system (AstroRx®), produced by the company, were injected into the spinal fluid of patients, in a standard lumbar puncture procedure. Five ALS patients were injected with 100 million cells and five patients were injected with 250 million cells. The results of both doses demonstrated a high safety profile. No serious treatment-related side effects were reported and no side effects limiting the treatment dose were found. In order to determine initial efficacy, an analysis was performed comparing the rate of disease progression according to the ALSFRS-R index in the pre-treatment follow-up period and the post-treatment follow-up period. It was found that with both doses the rate of disease progression slowed significantly during the three months following injection. In light of these clinical trial results, in the next study, the company intends to examine if dosing every three months with the cellular off-the-shelf AstroRx® product prolongs the therapeutic effect. Kadimastem CEO Asaf Shiloni said, "In the past year, Kadimastem has experienced an unprecedented show of support from both existing and new investors. Today’s grant by the Israeli Innovation Authority is another strong endorsement of the company’s important work in developing an improved therapeutic treatment for the millions suffering from debilitating neurological diseases. Kadimastem is at an exciting turning point and this grant supports us with the necessary resources to advance the plans for the quantitative production of the company's flagship product - AstroRx®. In other words, after this past year’s fund raising, we now have the capital to create increased quantities of brain supporting cells, enough to truly make a big difference in helping the hundreds of thousands of ALS patients worldwide." Chief Scientist of Kadimastem Professor Michel Revel said, "We thank the Israel Innovation Authority for its continued support and for further helping Kadimastem to proceed on this very worthwhile journey." About Kadimastem: Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional, insulin producing, pancreatic islet cells intended to treat and cure patients with insulin-dependent diabetes. IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study. An INTERACT meeting took place with the FDA on October 7, 2021, where the diabetes treatment program was discussed, and the company received directions how to prepare its Pre-IND submission. In November 2021, the company announced its intention to list on NASDAQ. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement: This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Asaf Shiloni +972 73-797-1613 s.herzl@kadimastem.com Company Website https://www.kadimastem.com/

December 13, 2021 07:00 AM Eastern Standard Time

Image

Centre for Neuro Skills Introduces Telerehabilitation: Instant Access to Therapies, Staff and CNS Physicians

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, has introduced telerehabilitation services to offer patients greater flexibility in their therapy program. CNS’ telerehabilitation services offer enhancements beyond its previously offered telehealth program. Since the beginning of 2020, CNS has delivered more than 125,000 hours of telehealth care to patients. Using the RingCentral Video® platform, powered by Zoom, patients receive full rehabilitation at home, virtually access therapies, clinicians and their treatment team from their CNS clinic. “CNS cares about rehabilitation success both in-clinic and at home, and telerehabilitation therapies focus on building life skills that lead to independence,” said Chris Persel, Regional Director of Clinical Services and Director of Behavior Programming at Centre for Neuro Skills. “Now, in their own environment, patients can work with their therapy team using the telerehabilitation toolkit as a desktop box of essentials to help build memory, cognition, reasoning, dexterity, education and other personal management details.” Therapy in real-time: All treatment modules are provided and vital living skills are taught; in-clinic therapies are replicated in the patient’s home setting and staff can suggest adaptive aids by viewing the home environment; return-to-work scenarios that can be modeled and practiced at home; therapists teach safety skills that patients can practice in real time. Telerehabilitation kit: CNS sends a boxed kit of learning aids to telerehabilitation and some hybrid patients. Included is a user’s guide for navigating RingCentral Video, learning tools, notebooks, a calculator, pens, a water bottle and a desktop whiteboard. Hybrid rehabilitation: Patients can opt for both in-clinic and virtual treatment. Telemedicine: Patients, therapists and families can consult online with physicians. In a recent national survey by the Brain Injury Association of America, telehealth was found to be a highly effective therapy platform. According to the survey of more than 400 providers, 94% of therapists reported that their patients’ recovery progressed using telehealth. About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership, clinical staff or patients, please contact Robin Carr at (415) 971-3991 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 cns@landispr.com Company Website https://www.neuroskills.com/

December 10, 2021 06:17 AM Eastern Standard Time

Image

Nice Healthcare Partners with Capsule to Improve Access to Affordable Prescription Drugs

Nice Healthcare

Nice Healthcare, the clinic that comes to you, today announced that it has partnered with leading digital pharmacy Capsule - bringing effortless, free same-day medication delivery to Nice patients in the Twin Cities, Minnesota; Phoenix, Arizona; and Denver, Colorado. Beginning today, all Nice patients in those three markets can choose Capsule to easily manage and receive over 550 Nice formulary medications for zero cost, including free same-day delivery. Nice has integrated with Capsule’s proprietary APIs, enabling clinicians to provide the option to use Capsule via the Nice app, and will leverage Capsule when they prescribe medications. Nice Healthcare is reimagining the delivery of primary health care by combining innovation with the personal touch that has been lost in modern medicine. With Nice, a full-service clinic comes to you. The partnership with Capsule amplifies this benefit with medications delivered same-day to the home or office. Capsule benefits include effortless management and ordering of all 550+ common medications on Nice’s formulary - same-day, for zero cost. Patients will also receive free, same-day delivery for non-Nice formulary medications, OTC medications, and other common medical supplies. “The partnership with Capsule brings Nice’s patients a better pharmacy experience and same-day delivery for all their medication needs,” said Genevieve Swenson, FNP, Cofounder and COO for Nice Healthcare. “Nice was founded on the belief that healthcare should be simple, convenient and affordable for everyone - including those individuals and families who are socially and economically disadvantaged. This partnership further underscores our commitment to make a convenient healthcare option even better for patients and small business employers alike.” “We are excited to bring Capsule’s beloved consumer experience to Nice’s patients and help make it easier than ever before to get, manage, and stay on their medications,” said Eric Kinariwala, Founder and CEO of Capsule. “Our partnership is made possible by harnessing both Capsule and Nice’s proprietary technology platforms in a way unique to the healthcare system. This is healthcare – as it should be.” Key benefits of the Capsule partnership include: Free-same day hand delivery of acute and chronic medications to the patient’s door Patients can manage all of their medications from their phone, tablet, or computer Text, chat, or call expert pharmacists anytime To learn more about Nice Healthcare, visit www.nice.healthcare. About Nice Healthcare Nice Healthcare is redesigning comprehensive healthcare for small and medium-sized businesses by utilizing a mix of technology and in-home care. As an employee benefit, they offer employees and their households in-home and virtual primary care, virtual mental health therapy, and virtual physical therapy services. Their clinicians can also offer patients x-rays, 35 labs and blood draws and a formulary with over 550 medications with no out-of-pocket costs. Since launching in Minnesota in 2017, Nice has expanded its integrated care services to 12 states. About Capsule Capsule is rebuilding the pharmacy industry from the inside out with an emotionally resonant experience and technology that enables customized outcomes for doctors, hospitals, insurers, and manufacturers. Capsule has designed every aspect of the pharmacy experience to give consumers and partners the peace of mind of having their health looked after. Capsule is available in more than a dozen cities across the United States, with expansion plans to have the ability to reach 100 million Americans by year's end. For more information, please visit capsule.com Contact Details Nice Healthcare Karen Swim +1 586-461-2103 pr@nice.healthcare Company Website https://www.nice.healthcare

December 08, 2021 09:00 AM Eastern Standard Time

Unknown Causes of Kidney Disease Project: American Kidney Fund Convenes Working Groups to Advance Kidney Disease Diagnoses

American Kidney Fund

The American Kidney Fund (AKF) yesterday held a working session summit to advance the path forward toward uncovering the unknown causes of kidney disease. The working session was the latest convening of AKF’s Unknown Causes of Kidney Disease (UCKD) Project, which brings together thought leaders from across the renal community to address four areas that are critical to improving diagnosis and treatment of kidney disease. “Too many patients fall into late-stage kidney disease or kidney failure, without a clear understanding of why. This can have dire consequences, such as delayed treatment, additional comorbidities and even the loss of a transplanted kidney,” said LaVarne A. Burton, AKF President and CEO. “We are working to bring together a thoughtful, dedicated collaboration among the kidney care community, resulting in steady progress toward making systematic changes that will help reduce the number of patients unaware of the origins of their kidney disease.” During the summit, the UCKD Project’s three implementation groups discussed key goals, current progress, anticipated barriers and next steps on: Public policy: Ensuring equitable insurance coverage for patients seeking an accurate diagnosis, including policies that increase genetic testing coverage for kidney disease. Patient and caregiver empowerment: Creating a suite of resources and tools to empower patients to work effectively with their clinicians to secure an accurate diagnosis. Health care professional awareness and education: Addressing knowledge gaps among clinicians, beginning with conducting research with primary care physicians, nephrologists, urologists, endocrinologists, nurse practitioners and physician assistants. “Sanofi Genzyme has a long-standing commitment to improving the lives of people living with rare renal diseases, said Duane Clark, General Manager, US Rare Diseases, Sanofi Genzyme. “As part of that effort, we are proud to be an ongoing supporter of the important work of the American Kidney Fund and the Unknown Causes of Kidney Disease project, including sponsorship of the Dec. 6 Summit. We know that many people enter late-stage kidney failure without knowing the cause of their disease. The UCKD Summit offers a unique opportunity to bring a wide variety of stakeholders to the table to tackle the real problems in diagnosis and develop action plans, with the common hope of bringing solutions forward that benefit patients living with chronic kidney disease.” The UCKD Project is supported by Title Sponsor Sanofi Genzyme, Leadership Sponsors Natera and Vertex Pharmaceuticals, Inc. and Champion Sponsors Alexion Pharmaceuticals, Otsuka America Pharmaceutical, Inc. and Travere Therapeutics. Participants in yesterday’s summit included Alexion Pharmaceuticals, Alport Syndrome Foundation, Fabry Support and Information Group, Natera, National Minority Quality Forum, National Organization for Rare Disorders, National Society of Genetic Counselors, NephCure Kidney International, Otsuka America Pharmaceutical, Inc., Renal Physicians Association, Sanofi Genzyme, Travere Therapeutics and Vertex Pharmaceuticals, Inc. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Stefanie Tuck 202-470-1797 +1 978-390-1394 AKF@jpa.com Company Website https://www.kidneyfund.org/

December 07, 2021 09:00 AM Eastern Standard Time

Premier Allergist, formerly The Allergy & Asthma Center, Joins AllerVie Health and Expands AllerVie Footprint to 10 States and 64 Locations

AllerVie Health

Today, AllerVie Health, a national network of board-certified allergists and immunologists, welcomes Premier Allergist, formerly The Allergy & Asthma Center, to its national platform. With the addition of Premier Allergist, AllerVie adds 32 locations to its provider network, enters three new states, and densifies their existing presence in Virginia and Florida. Dr. Prasad M. Nataraj, MD, the owner and founder of Premier Allergist, joins AllerVie Health and will be serving in a new executive leadership role where his expertise in increasing access to care through allergy clinic growth will help propel the company’s national network expansion. Dr. Nataraj attended medical school at Jawaharlal Nehru Medical School in India, completed his residency at Cornell Hospital in New York, and completed fellowship at the Louisiana State University – Tulane combination program. Dr. Nataraj and his wife Radhika built Premier Allergist over the past 26 years through relentless dedication to their calling to provide patients with state-of-the-art techniques for treatment, testing, and diagnosis of allergy, asthma, and related immunological disorders. "We are thrilled to be able to expand our phenomenal patient base and the care we provide to our patients by partnering with AllerVie Health,” said Dr. Prasad M. Nataraj. “We look forward to utilizing their resources to improve care for our current patients and to amplify our reach to new patients in our current and new markets.” All Premier Allergist providers will continue to practice medicine and provide exemplary allergy and immunology services to patients from their current locations throughout Maryland, D.C, Virginia, Pennsylvania, and Florida, ensuring continuity of care for patients. By joining AllerVie Health, Premier Allergist will leverage AllerVie’s commitment to clinical research, innovation, and expansion of care allowing the combined organization to expand and enhance services to patients through new clinical research trials, innovative treatments, and other resources available across the nationwide network of providers. “AllerVie Health is a patient-first organization directed by and in support of board-certified allergists,” said Dr. Weily Soong, AllerVie Health Chief Medical Officer. “We believe that all people deserve access to evidence-based allergy diagnostics and treatments, as well as advancements in allergy therapeutics stemming from clinical research trials. With the inclusion of Premier Allergist to our network, we are thrilled to be adding new providers to our network who both believe and ensure that patients receive the best in life changing care every day - the ultimate AllerVie experience.” An organization of like-minded, patient-focused providers living out their commitment to improving people’s lives one patient at a time, AllerVie Health and Premier Allergist look forward to bringing more clinic access, job opportunities, and the gold standard of patient care to their communities. About AllerVie Health AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, serving patients across 10 states in 64 clinic locations. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, reclaim their lives, and live in freedom! To learn more, visit www.allervie.com. Contact Details Rachel Russell Chief Marketing Officer rrussell@allervie.com Weily Soong, MD Chief Medical Officer wsoong@allervie.com

December 06, 2021 12:00 PM Central Standard Time

Hong Kong Successfully Hosts the 18th World Congress of Chinese Medicine for the First Time

Hong Kong Tourism Board

HONG KONG SAR - Media OutReach - 6 December 2021 - The 18th World Congress of Chinese Medicine (WCCM), one of the world's largest academic events in the field of Traditional Chinese Medicine (TCM), was successfully held in Hong Kong for the first time at the Hong Kong Convention and Exhibition Centre on 4 December 2021. Officiating guests including: the Hon Mrs. Carrie Lam Cheng Yuet-ngor, Chief Executive of the Hong Kong Special Administrative Region, the People's Republic of China (6th from left), Mr. C Y Leung, GBM, GBS, JP, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference, the People's Republic of China (4th from right), Mr. Tan Tieniu, Vice Director of Liaison Office of the Central People's Government in the Hong Kong S.A.R. (4th from left), Professor Sophia Chan Siu-chee, JP, Secretary for Food and Health of Hong Kong Special Administrative Region, The People's Republic of China (3rd from right), Dr. Chui Tak-yi, JP, Under Secretary for Food and Health of Hong Kong Special Administrative Region, The People's Republic of China (3rd from left), Dr. Ronald Lam, JP, Director of Health of Hong Kong Special Administrative Region, The People's Republic of China (2nd from left), Dr. Margaret Chan Fung Fu-chun, former Director-General of the World Health Organization (2nd from right), Ms. Feng Jiu, Permanent President of Hong Kong Registered Chinese Medicine Practitioners Association (5th from left), Mr. Tommy Li Ying-sang, Chairman of the Federation of the Hong Kong Chinese Medicine Practitioners and Chinese Medicine Traders Association (1st from right), and Professor Lyu Aiping, Dean of School of Chinese Medicine, Hong Kong Baptist University (1st from left) joined hands to kick off The 18th World Congress of Chinese Medicine. The 18th World Congress of Chinese Medicine Thanks to the bidding efforts of the Hong Kong Registered Chinese Medicine Practitioners Association, which is a member of the Hong Kong Convention Ambassador (HKCA) programme, initiated by the Hong Kong Tourism Board (HKTB), in collaboration with the World Federation of Chinese Medicine Societies (WFCMS), the hybrid event attracted more than 2,000 TCM academics and experts, generated over 3.8 million views from over 60 countries and regions. As physical gatherings resumed for the first time since the pandemic started, WCCM provided a platform for participants to engage in meaningful dialogue, covering TCM practices, benefits, opportunities and challenges, and the development potential of TCM. Mr. Ma Jianzhong, President of WFCMS, said, "We are pleased to host this edition of WCCM in Hong Kong for the first time. Embracing Chinese philosophy and culture, Hong Kong is the ideal place for academic and cultural exchanges to explore the way forward for furthering the global development of TCM, and its role in combating the pandemic through collaboration between practitioners and public sectors." Mr. Sang Binsheng, Vice President and Secretary General of WFCMS added, "Hong Kong is renowned for being the 'World's Meeting Place' thanks to its globally accessible and convenient transport network, large-scale world-class venues, facilities and professional services. We look forward to gathering again in Hong Kong and navigating the future of TCM development together." With its unrivalled fundamentals, Hong Kong is the core international city in the Greater Bay Area, a super-connector in the Belt and Road Initiative, and the ideal platform to promote TCM on the global stage. HKTB Executive Director Mr Dane Cheng said, "Hong Kong enjoys unique geographical and cultural advantages, and is the ideal destination for international conventions. Many such events have taken place recently, demonstrating Hong Kong's ability to host large-scale global events safely and efficiently. Apart from TCM, Hong Kong will continue to leverage the city's advantages as an East-meets-West showcase to promote the very best of Chinese heritage." The congress received extensive support from government and industry bodies. The National Administration of TCM and the Hong Kong Food and Health Bureau acted as advisors, and it was organised by the WFCMS, along with the Hong Kong Registered Chinese Medicine Practitioners Association and the WFCM (Hong Kong) Council Members Association as local hosts. Hong Kong – A World-Class Medical Convention Hub Hong Kong is a cultural melting pot, bringing together the best that the world has to offer, demonstrating the true definition of 'East meets West', even in the field of medicine. With its high global professional standing in medical science, Hong Kong plays a bridging role to contribute to the further development of TCM, as well as many Western medical disciplines. This winter, the city will also play host to key medical conventions, including the International Annual Congress of the Endoscopic and Laparoscopic Surgeons of Asia (ELSA) 2021, and the Hong Kong International Dental Expo and Symposium (HKIDEAS) 2021, both of which are led by Convention Ambassadors of the two organisations under the HKCA programme. About the Hong Kong Convention Ambassador (HKCA) programme Initiated by the HKTB, the HKCA programme brings together distinguished leaders from business and professional bodies to make Hong Kong the premier choice for regional and global meetings, conventions and exhibitions. HKTB provides comprehensive professional support and services to HKCAs, from event planning, bidding and preparation to execution. For more details, visit www.mehongkong.com/hkca. Contact Details Hong Kong Tourism Board Ms Vanessa So +852 2807 6540 vanessa.so@hktb.com

December 06, 2021 09:00 AM Eastern Standard Time

Image

How to Figure Out Medicare and Choose the Right Plan

YourUpdateTV

Choosing a Medicare plan can feel overwhelming. Ten thousand baby boomers age into Medicare everyday with questions about getting the right, affordable healthcare coverage and finding a Medicare plan that fits their needs. Recently, Keira Krausz, the Chief Marketing Officer at ClearMatch™ Medicare, part of HealthPlanOne, teamed with YourUpdateTV on a satellite media tour to share tips on how to make this year’s Medicare enrollment less confusing. A video accompanying this announcement is available at: https://youtu.be/58vAvLAhVyIQ For nearly 63 million Medicare beneficiaries or individuals turning 65 who need affordable health plan coverage, Medicare’s Annual Enrollment Period is here, and it will end in December 7 th. Choosing a Medicare plan can feel overwhelming. According to a recent survey, 58 percent of Medicare members say they don’t look forward to reviewing their Medicare plan, with 23 percent of people sharing that reviewing their plan is as delightful as having a colonoscopy. In 2019, 71 percent of Medicare beneficiaries said they didn’t compare plans during the open enrollment period, according to a Kaiser study published last month. Not comparing plans is a missed opportunity – because each year plans and benefits change – it’s important for individuals to compare their options, and a broker like ClearMatch™ Medicare can easily provide you a simple comparison of best plans. ClearMatch™ Medicare is committed to “de-complexify” Medicare for customers across the country. They match each customer with the right plan at the right place to deliver better health and peace of mind. The company can support customers throughout their Medicare journey, with a focus on the long-term. ClearMatch agents guide customers at every step of the way, from identifying and enrolling in a plan to reviewing coverage each year to make sure customers get all the benefits they deserve. To learn more about this year’s Medicare’s Annual Enrollment period and ClearMatch™ Medicare, go to: clearmatchmedicare.com About Keira Krausz: An award-winning Direct-to-Consumer marketer, Krausz has spent her career focused on the melding of data-driven analytics and compelling creative. Krausz led the launch of the ClearMatch™ Medicare brand. The brand’s purpose is to match each customer with a Medicare plan that delivers the benefits the customer is entitled to, to support better health and deliver peace of mind. The company expects potential customers will benefit from its digital content and then leverage a hybrid approach – an ecommerce platform plus a licensed ClearMatch™ Medicare insurance agent – to gain a solid understanding of options and enroll in a plan. ClearMatch™ Medicare agents, supported by the company, then will build a long-term relationship with each customer to ensure satisfaction. From 2013-2018 Krausz was the CMO and EVP of Nutrisystem, Inc., where her team reversed a seven-year decline and returned the company to sustained growth, to nearly double revenue and quadruple EBITDA. Prior to Nutrisystem, Krausz held leadership positions at Time Inc. and the Reader’s Digest Association, Inc. Krausz attended Cornell University as an undergraduate and has an MBA from the Tuck School at Dartmouth College. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 03, 2021 12:00 PM Eastern Standard Time

Video

1 ... 162 163 164 165 166 ... 210

Back